KDM1A and acute myeloid leukemia: Finally, the frequently promoting effect of LSD1 inhibition on the differentiation of normal SCs is increasingly used as a therapeutic approach in the most undifferentiated and aggressive human malignancies (AML, glioblastoma, or HCC) [121,131,132] with promising preclinical outcomes, validating their entry into clinical trials (Table 1 and Table 2).